Abstract
Background: The importance of the issue of the economic burden of treatment and care for people with dementia is crucial in the developed countries. The European Union and other developed countries are trying to improve the course of aging population which leads to rising costs. Their uniform registration is also one of the objectives of the developed countries’ strategic plans to fight dementia. The individual steps of the plans in practical terms so far are mainly directed to the early diagnosis of diseases, records of the associated data are so far in the background.
Aim: The aim of this paper is to specify a set of costs that should be constantly monitored at the national level within dementia.
Methods: The main method is a literature review focused on Alzheimer's disease. The searched keywords were "Alzheimer's disease" and "costs" incurred after 2010. The studies will specify the monitored costs and determine their minimal penetration, which will then form the basis for recommendations for the monitored group of costs on a national level.
Results: Results of the analysis indicate that the following main cost groups are monitored: medical direct costs (inpatient care, outpatient treatment, medication), non-medical direct costs (day care centres, community health services, respite care, accommodation costs for patients) and indirect costs (time that the carers dedicate to the patient). The issue of different naming and groups of costs calls for a common strategy in this area and defining the minimum items that should be monitored.
Keywords: Cost classification, dementia, Alzheimer's disease, direct costs, indirect costs, aging.
Current Alzheimer Research
Title:Missing Uniform Costs Classification for Alzheimer’s Disease Treatment and Care
Volume: 15 Issue: 14
Author(s): Petra Maresova and Kamil Kuca*
Affiliation:
- Faculty of Informatics and Management, Centre of Basic and Applied Research, University of Hradec Kralove, Hradec Kralove,Czech Republic
Keywords: Cost classification, dementia, Alzheimer's disease, direct costs, indirect costs, aging.
Abstract: Background: The importance of the issue of the economic burden of treatment and care for people with dementia is crucial in the developed countries. The European Union and other developed countries are trying to improve the course of aging population which leads to rising costs. Their uniform registration is also one of the objectives of the developed countries’ strategic plans to fight dementia. The individual steps of the plans in practical terms so far are mainly directed to the early diagnosis of diseases, records of the associated data are so far in the background.
Aim: The aim of this paper is to specify a set of costs that should be constantly monitored at the national level within dementia.
Methods: The main method is a literature review focused on Alzheimer's disease. The searched keywords were "Alzheimer's disease" and "costs" incurred after 2010. The studies will specify the monitored costs and determine their minimal penetration, which will then form the basis for recommendations for the monitored group of costs on a national level.
Results: Results of the analysis indicate that the following main cost groups are monitored: medical direct costs (inpatient care, outpatient treatment, medication), non-medical direct costs (day care centres, community health services, respite care, accommodation costs for patients) and indirect costs (time that the carers dedicate to the patient). The issue of different naming and groups of costs calls for a common strategy in this area and defining the minimum items that should be monitored.
Export Options
About this article
Cite this article as:
Maresova Petra and Kuca Kamil *, Missing Uniform Costs Classification for Alzheimer’s Disease Treatment and Care, Current Alzheimer Research 2018; 15 (14) . https://dx.doi.org/10.2174/1567205015666180831103018
DOI https://dx.doi.org/10.2174/1567205015666180831103018 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Steroids and Androgen Antagonists used as Neuroprotection in Common Neurological Disorders
CNS & Neurological Disorders - Drug Targets Serotonergic 5-HT<sub>6</sub> Receptor Antagonists: Heterocyclic Chemistry and Potential Therapeutic Significance
Current Topics in Medicinal Chemistry Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study
Current Alzheimer Research Oxidative Stress, Inflammation and Endothelial Biomarkers in Arterial Hypertension
Current Hypertension Reviews Gender, Hormones and the Transmissible Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hyphenated Mass Spectrometry Techniques in the Diagnosis of Amyloidosis
Current Medicinal Chemistry Comprehensive Review On Oral Disintegrating Films
Current Drug Delivery Multi-Target Compounds Acting in the Central Nervous System Designed From Natural Products
Current Medicinal Chemistry Connecting Parkinsons Disease and Drug Addiction: Common Players Reveal Unexpected Disease Connections and Novel Therapeutic Approaches
Current Pharmaceutical Design Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia
Current Neurovascular Research Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies
Current Medicinal Chemistry Review of Vital Signs Monitoring Systems – Patient’s Acceptability, Issues and Challenges
Neuroscience and Biomedical Engineering (Discontinued) Molecular Dynamics and Regulation of Butyrylcholinesterase Cholinergic Activity by RNA Binding Proteins
CNS & Neurological Disorders - Drug Targets Protein Aggregation and Its Consequences for Human Disease
Protein & Peptide Letters Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain
CNS & Neurological Disorders - Drug Targets Chlorella vulgaris: A Multifunctional Dietary Supplement with Diverse Medicinal Properties
Current Pharmaceutical Design Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry New Developments in Anti-Platelet Therapies Potential Use of CD39/Vascular ATP Diphosphohydrolase in Thrombotic Disorders
Current Drug Targets Regional Cerebral Blood Flow and Cerebrovascular Reactivity in Alzheimer’s Disease and Vascular Dementia Assessed by Arterial Spinlabeling Magnetic Resonance Imaging
Current Neurovascular Research